(Q34439681)

2 August 2017

1 reference

title

What a difference a year makes: reflections on the ACR recommendations for the medical management of osteoarthritis (English)

1 reference

2 August 2017

1 reference

Hochberg MC

1

1 reference

2 August 2017

publication date

1 December 2001

1 reference

Current Rheumatology Reports

2 August 2017

published in

1 reference

2 August 2017

volume

3

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

473-478

1 reference

North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Dr

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-001-0060-Z

Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-001-0060-Z

Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-001-0060-Z

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-001-0060-Z

Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study

21 January 2018

1 reference

12 December 2020

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

1 reference

12 December 2020

Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group

1 reference

12 December 2020

A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

12 December 2020

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

12 December 2020

Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition

1 reference

12 December 2020

EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

1 reference

12 December 2020

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study

1 reference

12 December 2020

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

12 December 2020

Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis

1 reference

12 December 2020

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

12 December 2020

Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice

1 reference

12 December 2020

Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis

1 reference

12 December 2020

Non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents

1 reference

12 December 2020

Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip

1 reference

12 December 2020

Acupuncture for osteoarthritis of the knee: a systematic review

1 reference

12 December 2020

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

12 December 2020

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

12 December 2020

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

12 December 2020

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

1 reference

12 December 2020

Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

1 reference

12 December 2020

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

1 reference

12 December 2020

Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis

1 reference

12 December 2020

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

1 reference

12 December 2020

Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia

1 reference

12 December 2020

Recommendations for the clinical use of cyclooxygenase-2-specific inhibitors

1 reference

12 December 2020

Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors

1 reference

12 December 2020

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

12 December 2020

Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines

1 reference

12 December 2020

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

12 December 2020

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

1 reference

12 December 2020

An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference

1 reference

12 December 2020

Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

10.1007/S11926-001-0060-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1041185840

0 references

1 reference